Key Highlights

  • Third quarter loss per share was USD 0.46, narrower than the estimated USD 0.52 loss, with no Revenue reported.
  • Cash, cash equivalents and marketable securities were USD 82.9 million at September 30, 2026, per the quarterly filing.
  • Net loss for the nine months was USD 33.4 million, the same as the prior-year period.
  • No shares had been sold under the company's at-the-market offering as of September 30, per the filing.

Kalaris Therapeutics (NASDAQ:KLRS), a clinical-stage ophthalmology company, reported a third quarter 2026 loss of USD 0.46 per share, narrower than the USD 0.52 estimated loss. The company reported no revenue. Net loss for the nine months ended September 30 was USD 33.4 million, equal to the USD 33.4 million recorded in the same period of 2025.

Operations used USD 33.2 million of cash in the nine months, compared with USD 31.3 million a year earlier. The accumulated Deficit was USD 193.4 million, up from USD 160.0 million at December 31, 2025.

Candidate and Corporate Background

The company is developing TH103, a clinical-stage anti-vascular endothelial growth Factor drug engineered for extended intraocular retention and enhanced VEGF inhibition. It is aimed at patients with exudative or neovascular retinal diseases. The quarterly filing says the company's Business depends on TH103 receiving Marketing approval, and that delays in approval or commercialization would harm its business.

The company's current structure follows a Merger with AlloVir. Historical results through 2025 reflect only the accounts of the legacy private company, and historical share data were recast using an exchange ratio of 0.2016 per share set out in the merger agreement. The filing says funding since inception has come from preferred stock sales, convertible notes, a simple agreement for future equity, cash received in the merger and a 2025 private placement.

Liquidity and Funding Options

Cash, cash equivalents and marketable securities were USD 82.9 million at September 30. The filing lists the need for substantial additional funding among its principal risks and notes that early-stage trial and preclinical results may not predict later results.

On April 3, 2026 the company filed a shelf registration on Form S-3, declared effective April 13, and set up an at-the-market offering. As of September 30 no shares had been sold under it, and USD 0.5 million of deferred Transaction Costs related to the offering were capitalized in current assets. No pre-funded warrants remained outstanding at quarter end.

General and administrative costs for services from a related party under a business support agreement were immaterial in the third quarter, against USD 0.1 million a year earlier, and USD 0.2 million for the nine months, against USD 0.3 million.

The summary risk factors state the company needs substantial additional funding for continuing operations, and that its business could be materially harmed if it cannot commercialize TH103 or other candidates it develops.

Items to Follow

Quarterly cash use against the USD 82.9 million balance, any use of the at-the-market program, and disclosures on TH103's clinical development are the items to track. Because net loss for the nine months matched the prior year, spending trends in the fourth quarter is a useful comparison.